Disease Markers / 2017 / Article / Tab 1

Research Article

Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma

Table 1

Patients’ characteristics ().

CharacteristicN (%)

GenderMale151 (75.9)
Female48 (24.1)

AgeMedian (25%–75%)66 (58–72)

StageI13 (6.5)
II53 (26.6)
III61 (30.7)
IV54 (27.1)
Peritoneal18 (9.0)

Histological typeEpithelioid143 (71.9)
Biphasic25 (12.6)
Sarcomatoid21 (10.6)
Not characterized10 (5.0)

ECOG performance status010 (5.0)
195 (47.7)
284 (42.2)
310 (5.0)

C-reactive proteinMedian (25%–75%)23 (10–68.3) [29]

Asbestos exposureNot exposed43 (22.3) [6]
Exposed150 (77.7)

SmokingNonsmokers95 (49.0) [5]
Smokers99 (51.0)

Type of chemotherapyGemcitabine/cisplatin123 (61.8)
Pemetrexed/cisplatin48 (24.1)
Other11 (5.5)
None17 (8.6)

Response rateCR7 (4.1) [27]
PR57 (33.1)
SD86 (50.0)
PD22 (12.8)

Time to progressionMedian (25%–75%)7.67 (5.27–13.80)

Overall survivalMedian (25%–75%)16.30 (9.07–26.80)

Follow-upMedian (25%–75%)69.67 (22.00–81.53)

Numbers in square brackets denote the number of patients with missing data. CR: complete response; ECOG: Eastern Cooperative Oncology Group; PD: progressive disease; PR: partial response; SD: stable disease.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.